Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

BACKGROUND: Rituximab has been confirmed to improve the survival of patients with B cell indolent non-Hodgkin lymphomas (B-iNHLs) in Western world as previously reported, however, it is rarely reported in Chinese cohort. This study is to investigate the efficacy and safety of rituximab-based chemoim...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zengjun, Li, Fei, Yi, Shuhua, Gu, Zhimin, Yu, Zhen, Xu, Yan, Feng, Xiaoyan, Liu, Wei, Zou, Dehui, Qi, Junyuan, Zhan, Fenghuang, Qiu, Lugui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517647/
https://www.ncbi.nlm.nih.gov/pubmed/26219471
http://dx.doi.org/10.1186/s12885-015-1534-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517647/
https://www.ncbi.nlm.nih.gov/pubmed/26219471
http://dx.doi.org/10.1186/s12885-015-1534-0

Ejemplares similares